Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Hai‐Dong Zhu(Zhongda Hospital Southeast University), Jian Wang(Nanfang Hospital), Xu Zhu(Children's Hospital of Chongqing Medical University), Jianbing Wu(Nanchang University), Ming Huang, Wei Mu(Beihang University), Jiaping Li(Sun Yat-sen University), Bin‐Yan Zhong(Soochow University), Shu-Wei Wen(Shanxi Provincial Cancer Hospital), Jinhua Huang(Sun Yat-sen University), Yusheng Song(Ganzhou People's Hospital), Junhui Sun(First Affiliated Hospital Zhejiang University), Zishu Zhang(Hunan University of Traditional Chinese Medicine), Qiang Tu(Nanjing Jiangning Hospital), Mingsheng Huang(Sun Yat-sen University), Shanzhi Gu(Central South University), Wenhao Hu(Sun Yat-sen University), Song Wang(CytomX Therapeutics (United States)), Wenhui Li(Zero to Three), Weidong Wang(Sun Yat-sen University), Jian Xu(Nanjing General Hospital of Nanjing Military Command), Hai-Liang Li(Zhengzhou University), Hui Zhao(Nantong University), Wei Zhao(Chongqing Emergency Medical Center), Wenge Xing(Tianjin Medical University Cancer Institute and Hospital), Zhi‐Cheng Jin(Zhongda Hospital Southeast University), Wen‐Bin Ding, Zaiming Lu(China Medical University), Naijian Ge(Second Military Medical University), Qi Wang(Fujian Medical University), Yanming Lei(Tibet Autonomous Region People's Hospital), Guowen Yin(Jiangsu Cancer Hospital), Xuya Zhao(Fujian Medical University), Jian-Jia Chen(TU Dortmund University), Jinwei Zhao(Nantong Tumor Hospital), Chunwang Yuan(Capital Medical University)
Signal Transduction and Targeted Therapy
February 8, 2023
Cited by 295


Related Papers